SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals inches up as its arm launches Lacosamide Injection

05 Jun 2026 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 2183.30, up by 1.85 points or 0.08% from its previous closing of Rs. 2181.45 on the BSE.

The scrip opened at Rs. 2185.30 and has touched a high and low of Rs. 2215.00 and Rs. 2181.00 respectively. So far 6145 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1515.55 on 05-Jun-2025.

Last one week high and low of the scrip stood at Rs. 2,439.70 and Rs. 2144.40 respectively. The current market cap of the company is Rs. 62329.69 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.67% and 13.68% respectively.

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc.

According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market achieved annual sales of around $15.2 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.

Glenmark Pharma Share Price

2155.60 -17.60 (-0.81%)
15-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1279.25
Cipla 1381.50
Zydus Lifesciences 1087.75
Lupin 2273.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: